Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of HEM1036 in Subjects With Low Anterior Resection Syndrome (LARS)

NCT05527301 is registered in ClinicalTrials.gov with HEM Pharma Inc. as lead sponsor.

NCT NCT05527301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05527301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of HEM1036 in Subjects With Low Anterior Resection Syndrome (LARS)
Lead sponsor
HEM Pharma Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2024
Completion date
January 1, 2026
Enrollment
67 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lars - low anterior resection syndrome